Squamous Cell Skin Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Skin Cancer (1090)

Bowens Disease (2)

Skin Cancer (1090)

Bowens Disease (2)

›

No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2
No biomarker	Bowens Disease	No biomarker	Bowens Disease	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2
No biomarker	Bowens Disease	No biomarker	Bowens Disease	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 expression	Squamous Cell Skin Cancer	PD-L1 expression	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
TMB-H	Squamous Cell Skin Cancer	TMB-H	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
CCND1 overexpression	Squamous Cell Skin Cancer	CCND1 overexpression	Squamous Cell Skin Cancer	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
TMB-H + PD-L1 expression	Squamous Cell Skin Cancer	TMB-H + PD-L1 expression	Squamous Cell Skin Cancer	pembrolizumab + panitumumab Sensitive: C4 – Case Studies pembrolizumab + panitumumab Sensitive : C4	pembrolizumab + panitumumab Sensitive: C4 – Case Studies pembrolizumab + panitumumab Sensitive : C4
ERBB3 R135C + TMB-H	Squamous Cell Skin Cancer	ERBB3 R135C + TMB-H	Squamous Cell Skin Cancer	nivolumab + lapatinib Sensitive: C4 – Case Studies nivolumab + lapatinib Sensitive : C4	nivolumab + lapatinib Sensitive: C4 – Case Studies nivolumab + lapatinib Sensitive : C4
SRC amplification	Squamous Cell Skin Cancer	SRC amplification	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
TP53 mutation	Squamous Cell Skin Cancer	TP53 mutation	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
BRCA2 deletion	Squamous Cell Skin Cancer	BRCA2 deletion	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
NGFR overexpression	Squamous Cell Skin Cancer	NGFR overexpression	Squamous Cell Skin Cancer	5-fluorouracil Sensitive: D – Preclinical 5-fluorouracil Sensitive : D	5-fluorouracil Sensitive: D – Preclinical 5-fluorouracil Sensitive : D
NGFR overexpression	Squamous Cell Skin Cancer	NGFR overexpression	Squamous Cell Skin Cancer	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D

Squamous Cell Skin Cancer

Associations(22)

Associations
(22)